NCT02484456View on ClinicalTrials.gov

Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 14, 2015

Primary Completion Date

February 21, 2019

Study Completion Date

December 3, 2019

Conditions
Major Depression
Interventions
DRUG

AV 101 (4-Chlorokynurenine)

L-4-chlorokynurenine (4-Cl-KYN) was developed as a prodrug that is rapidly converted in vivo to its active metabolite 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized N-Methyl-D-aspartate receptor (NMDAR) antagonist at the glycine site.

OTHER

Placebo Comparator

Placebo

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Mental Health (NIMH)

NIH

NCT02484456 - Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder | Biotech Hunter | Biotech Hunter